Two Sigma Investments’s Acrivon Therapeutics ACRV Stock Holding History

Two Sigma Investments’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Buy	641,498 +252,103	+65%	+$428K	﹤0.01%	3508
2026 Q1	$541K	Sell	389,395 -195,674	-33%	-$341K	﹤0.01%	3690
2025 Q4	$1.41M	Buy	585,069 +265,864	+83%	+$578K	﹤0.01%	2701
2025 Q3	$578K	Buy	319,205 +138,033	+76%	+$194K	﹤0.01%	2918
2025 Q2	$216K	Buy	+181,172	New	+$249K	﹤0.01%	2892
2023 Q1	–	Sell	-21,534	Closed	-$248K	–	2923
2022 Q4	$248K	Buy	+21,534	New	+$273K	﹤0.01%	2318

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments's ACRV Position: Q2 2026 in Review

Two Sigma Investments increased its Acrivon Therapeutics (ACRV) stake by 65% in Q2 2026, buying an estimated $428K and bringing the position to 641,498 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #3508.

Two Sigma Investments first reported a position in ACRV in Q4 2022 and has held it in 6 quarters since. The position peaked at $1.41M in Q4 2025. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

Two Sigma Investments held 641,498 shares of Acrivon Therapeutics worth $1.14M as of Q2 2026.
Two Sigma Investments bought 252,103 Acrivon Therapeutics shares in Q2 2026, an estimated $428K.
Acrivon Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q2 2026, its #3508 holding.
Two Sigma Investments first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 6 quarters since.
Two Sigma Investments's Acrivon Therapeutics position peaked at $1.41M in Q4 2025.
46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.